Raptor Pharmaceutical Obtains Tissue Fibrotic Disease Intellectual Property Related to Cysteamine

NOVATO, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) — Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (RPTP), today announced that the Company has acquired exclusive world-wide rights to intellectual property related to cysteamine and …

Share